Levilimab information

Levilimab
Monoclonal antibody
Type	?
Clinical data
ATC code	L04AC25 (WHO) ;
Legal status
Legal status	Investigational;
Identifiers
CAS Number	2035008-70-7;
UNII	P7UV3L2H80;
KEGG	D12748;

Levilimab is an anti-IL-6 monoclonal antibody initially developed to treat rheumatoid arthritis. In 2020, it was approved as a treatment for COVID-19 in Russia.^[1]^[2]^[3]

^ Harrison, Charlotte (1 August 2020). "Focus shifts to antibody cocktails for COVID-19 cytokine storm". Nature Biotechnology. 38 (8): 905–908. doi:10.1038/s41587-020-0634-9. ISSN 1546-1696. PMID 32760027. S2CID 220980850.
^ Gomon, Y. M.; Strizheletsky, V. V.; Ivanov, I. G.; Balykina, Y. E.; Ermolyev, M. V.; Kolbin, A. S.; Livshits, M. V.; Usmanova, T. A.; Fakhrutdinova, A. M.; Konstantinova, Y. S.; Gubanov, A. P. (2023). "Efficiency of Levilimab in patients with moderate and severe COVID-19". Farmakoekonomika (in Russian). pp. 36–47. Retrieved 4 November 2023.
^ Lomakin, Nikita V.; Bakirov, Bulat A.; Protsenko, Denis N.; Mazurov, Vadim I.; Musaev, Gaziyavdibir H.; Moiseeva, Olga M.; Pasechnik, Elena S.; Popov, Vladimir V.; Smolyarchuk, Elena A.; Gordeev, Ivan G.; Gilyarov, Mikhail Yu; Fomina, Darya S.; Seleznev, Anton I.; Linkova, Yulia N.; Dokukina, Ekaterina A.; Eremeeva, Anna V.; Pukhtinskaia, Polina S.; Morozova, Maria A.; Zinkina-Orikhan, Arina V.; Lutckii, Anton A. (December 2021). "The efficacy and safety of levilimab in severely ill COVID-19 patients not requiring mechanical ventilation: results of a multicenter randomized double-blind placebo-controlled phase III CORONA clinical study". Inflammation Research. 70 (10–12): 1233–1246. doi:10.1007/s00011-021-01507-5. ISSN 1420-908X. PMC 8479713. PMID 34586459.

[1] Harrison, Charlotte (1 August 2020). "Focus shifts to antibody cocktails for COVID-19 cytokine storm". Nature Biotechnology. 38 (8): 905–908. doi:10.1038/s41587-020-0634-9. ISSN 1546-1696. PMID 32760027. S2CID 220980850.

[2] Gomon, Y. M.; Strizheletsky, V. V.; Ivanov, I. G.; Balykina, Y. E.; Ermolyev, M. V.; Kolbin, A. S.; Livshits, M. V.; Usmanova, T. A.; Fakhrutdinova, A. M.; Konstantinova, Y. S.; Gubanov, A. P. (2023). "Efficiency of Levilimab in patients with moderate and severe COVID-19". Farmakoekonomika (in Russian). pp. 36–47. Retrieved 4 November 2023.

[3] Lomakin, Nikita V.; Bakirov, Bulat A.; Protsenko, Denis N.; Mazurov, Vadim I.; Musaev, Gaziyavdibir H.; Moiseeva, Olga M.; Pasechnik, Elena S.; Popov, Vladimir V.; Smolyarchuk, Elena A.; Gordeev, Ivan G.; Gilyarov, Mikhail Yu; Fomina, Darya S.; Seleznev, Anton I.; Linkova, Yulia N.; Dokukina, Ekaterina A.; Eremeeva, Anna V.; Pukhtinskaia, Polina S.; Morozova, Maria A.; Zinkina-Orikhan, Arina V.; Lutckii, Anton A. (December 2021). "The efficacy and safety of levilimab in severely ill COVID-19 patients not requiring mechanical ventilation: results of a multicenter randomized double-blind placebo-controlled phase III CORONA clinical study". Inflammation Research. 70 (10–12): 1233–1246. doi:10.1007/s00011-021-01507-5. ISSN 1420-908X. PMC 8479713. PMID 34586459.

Levilimab information

and 27 Related for: Levilimab information

Levilimab

Dupilumab

Tocilizumab

Ustekinumab

Secukinumab

Ixekizumab

Guselkumab

Interleukin 6

Interleukin 1 beta

Anakinra

CD4

Interleukin 12

Daclizumab

Benralizumab

Basiliximab

Interleukin 23

Mepolizumab

Interleukin 23 subunit alpha

Canakinumab

Interleukin

Interleukin 17

Interleukin 2

Interleukin 40

Interleukin 10

Lebrikizumab

Interleukin 5

IL2RA